Myelofibrosis News and Research

RSS

An ActRIIA fusion protein got FDA approved for PAH treatment

On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment. PAH, characterized by elevated blood pressure in the arteries connecting the heart and lungs, poses a grave risk of heart failure.

From Sino Biological Inc. 28 Mar 2024

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

Annual NCCN Congress to focus on latest advances in blood cancer treatment

The National Comprehensive Cancer Network 2023 Annual Congress: Hematologic Malignancies returns to San Francisco this week, for the first time since 2019.

19 Sep 2023

Chronic inflammation's influence on TP53 mutations in leukemia evolution explored in new study

Researchers performed a multi-omics evaluation of HSPCs obtained from individuals with myeloproliferative neoplasms transforming to TP53-related secondary forms of acute myeloid leukemia.

7 Sep 2023

Adoption of Mediterranean diet shows promise in easing symptoms for myeloproliferative neoplasm patients

Researchers assess the feasibility of an education-focused Mediterranean diet intervention among myeloproliferative neoplasm patients.

25 May 2023

Cancer patients can initiate SARS-CoV-2 vaccination three months after bone marrow transplant

Patients with cancer whose immune systems are being supported or rebuilt by bone marrow transplantation should begin receiving vaccines for protection against SARS-CoV-2 three months post-transplant, according to a large, prospective, observational study led collaboratively by the Center for International Blood and Marrow Transplant Research, the Blood & Marrow Transplant Clinical Trials Network and Fred Hutchinson Cancer Center.

16 May 2023

Small molecule inhibitor reverses malignant hyper-editing by an inflammation-induced protein isoform

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

16 Feb 2023

Patients with myelofibrosis show improvement in disease-related symptoms when treated with momelotinib

Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 Jan 2023

Researchers make first bone marrow 'organoids' to capture key features of human bone marrow

Scientists from Oxford University and the University of Birmingham have made the first bone marrow 'organoids' that capture the key features of human bone marrow.

15 Nov 2022

Pioneering research identifies a promising treatment approach for myelofibrosis

Pioneering research into the chronic inflammation often seen in certain blood cancers has identified a promising treatment approach for myelofibrosis, a potentially deadly bone marrow cancer.

9 Nov 2022

New anti-cancer drug candidate is absorbed through the lymphatic system rather than blood vessels

A team of University of Michigan researchers is developing a new anti-cancer drug that is absorbed through the gut's lymphatic system rather than blood vessels, potentially outmaneuvering the molecular signaling pathways that lead to drug resistance while increasing cancer-fighting ability and reducing side effects.

17 Aug 2022

Study sheds new light on the role of transcription factors in bone marrow microenvironments

In your home, storing books on a bookshelf, tools in a tool box, and a broom in a broom cupboard makes it easy to access these items whenever you need them.

9 Jun 2022

Oral pill taken once a day improves outcomes of patients with myelofibrosis

Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7.

7 Jun 2022

Novel therapy found to be safe and well-tolerated in patients with bone marrow cancer

Mount Sinai physician-scientists have found that a novel therapy for the bone marrow cancer myelofibrosis is safe and well-tolerated and is associated with modest improvements in patients in a Phase 1b clinical trial.

12 Dec 2021

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers in the UK have provided evidence that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces effective immune responses in patients with myeloproliferative neoplasms.

13 May 2021

Study finds two drugs capable of slowing bone marrow cancer progression

Primary myelofibrosis (PMF), a relatively rare but painful type of bone marrow cancer, disrupts the body's normal production of blood cells by causing extensive scarring in the bone marrow.

22 Mar 2021

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Since stem cells can continually self-regenerate, making more stem cells, and differentiate into many different specialized cell types, they play an important role in our development and health.

26 Jan 2021

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR).

10 Dec 2020

Novel super-activating macrophage receptor could explain hyper-inflammation in severe COVID-19

Immunity is a curious thing. While essential in protecting the body against invading pathogens and foreign antigens, it can also turn against the body and trigger destructive immunological processes. A new study published on the preprint server bioRxiv* in November 2020 reports on the role played by hyperactive macrophages in a range of acute and chronic hyper-inflammatory conditions.

10 Nov 2020